An FDA panel of outside experts is slated to review Egalet Corp.‘s (EGLT) new drug application for ARYMO ER extended-release tablets, an abuse-deterrent, oral morphine product candidate, on August 4, 2016.The company is seeking approval of ARYMO ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.The FDA’s final decision is scheduled for October 14, 2016.Last month, an FDA panel recommended two abuse-deterrent opioids namely Pfizer’s ALO-02 and Teva’s Vantrela ER for approval. ALO-02 and Vantrela ER are also intended for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.